“Since the initial discovery of HCV infection, development of tolerable antiviral therapies has revolutionized its treatment,” Andrew H. Talal, MD, MPH, and colleagues wrote. “However, we are far from having won the war against the virus. Entry into HCV care among persons with [substance use disorders] unfortunately remains severely restricted, largely because of their inability to access appropriate HCV management.”